ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more
ProKidney Corp. (PROK) - Total Assets
Latest total assets as of September 2025: $351.61 Million USD
Based on the latest financial reports, ProKidney Corp. (PROK) holds total assets worth $351.61 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ProKidney Corp. - Total Assets Trend (2019–2024)
This chart illustrates how ProKidney Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ProKidney Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
ProKidney Corp.'s total assets of $351.61 Million consist of 89.8% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.5% |
| Accounts Receivable | $2.45 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how ProKidney Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProKidney Corp.'s current assets represent 89.8% of total assets in 2024, an increase from 78.7% in 2019.
- Cash Position: Cash and equivalents constituted 22.5% of total assets in 2024, down from 77.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
ProKidney Corp. Competitors by Total Assets
Key competitors of ProKidney Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ProKidney Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ProKidney Corp. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ProKidney Corp. is currently not profitable relative to its asset base.
ProKidney Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.32 | 17.09 | 1.02 |
| Quick Ratio | 10.32 | 17.09 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $270.93 Million | $ 405.04 Million | $ 83.00K |
ProKidney Corp. - Advanced Valuation Insights
This section examines the relationship between ProKidney Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 97.15 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | $441.07 Million |
| Market Capitalization | $194.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values ProKidney Corp.'s assets below their book value (0.44 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ProKidney Corp.'s assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ProKidney Corp. (2019–2024)
The table below shows the annual total assets of ProKidney Corp. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $441.07 Million | +4.88% |
| 2023-12-31 | $420.55 Million | -18.81% |
| 2022-12-31 | $518.00 Million | +1185.41% |
| 2021-12-31 | $40.30 Million | +141.31% |
| 2020-12-31 | $16.70 Million | -14.83% |
| 2019-12-31 | $19.61 Million | -- |